Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 4 of 4 results for solriamfetol

  1. Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy (TA758)

    Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by narcolepsy in adults.

    Technology appraisal guidance
    Published
    5 January 2022
    View recommendations

    Sections for TA758

  2. Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA777)

    Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.

    Technology appraisal guidance
    Published
    9 March 2022
    View recommendations

    Sections for TA777

  3. Oveporexton for treating type 1 narcolepsy [ID6622]

    In development Reference number: GID-TA11820 Expected publication date:  14 April 2027

    Technology appraisal guidance
    In development

  4. Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA776)

    Evidence-based recommendations on pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.

    Technology appraisal guidance
    Published
    9 March 2022
    View recommendations

    Sections for TA776